Bio Essence Corp announced the commencement of a Regulation A Tier 2 offering to raise up to $5.0 million in February 2026. The company also disclosed ongoing legal proceedings alleging breach of contract and lease obligations with claimed damages of approximately $1.5 million.

• In February 2026, Bio Essence Corp announced the commencement of a Regulation A Tier 2 offering for up to $5.0 million to raise capital [N1].
• The company is a defendant in a legal complaint filed in February 2026 alleging breach of contract and lease obligations related to a commercial space, with claimed damages of $1,504,823.81; Bio Essence denies the allegations and plans to bring counterclaims [S1].

Bio Essence has demonstrated the ability to generate revenues and net income despite operational restructuring and outsourcing manufacturing. The company’s recent capital raise via Regulation A Tier 2 offering could provide additional resources to support growth or operational stability. Its focus on herbal health and traditional Chinese medicine supplements taps into a growing consumer interest in natural health products. The company’s streamlined operations and direct management may improve agility and cost control.

The company faces significant liquidity challenges, with a current ratio well below 1 and minimal cash reserves, which may constrain operational flexibility. The ongoing legal dispute alleging breach of contract and lease obligations with substantial claimed damages poses financial and reputational risks. The company’s accumulated deficit and negative stockholders’ equity reflect historical financial difficulties. Outsourcing manufacturing may reduce control over product quality and supply chain reliability. The small employee base may limit capacity for growth and operational execution.

Bio Essence operates in the niche herbal health and nutritional supplements market, leveraging expertise in traditional Chinese medicines and dietary supplements. Its prior vertical integration through subsidiaries provided manufacturing capabilities, but the company now outsources these services, which may reduce operational control. The company’s small scale, specialized product focus, and OEM service offerings may provide some differentiation, but limited scale and financial constraints reduce barriers to entry and competitive advantages.

• Liquidity Risk: The company has a low current ratio of 0.17 and a cash ratio of 0.01 as of December 31, 2025, indicating potential difficulties in meeting short-term obligations.
• Legal Risk: Bio Essence is involved in a legal complaint alleging breach of contract and lease obligations with claimed damages of approximately $1.5 million, which could impact financial position and operations.
• Operational Risk: Outsourcing manufacturing after disposal of subsidiaries may reduce control over production quality and supply chain, potentially affecting product delivery and customer satisfaction.
• Financial Risk: The company has a significant accumulated deficit and negative stockholders’ equity, reflecting ongoing financial challenges that may affect sustainability.

• Bio Essence Corp is an herbal health, diet, and nutrition company focused on providing herbal health, diet, and vitamin nutritional supplements [S1].
• The company was incorporated in California on January 1, 2000, and underwent a change of control in 2016 with Jian Yang acquiring controlling interest [S1].
• Bio Essence previously operated through subsidiaries including Bio Essence Pharmaceutical, Inc. (BEP), Bio Essence Herbal Essentials Inc. (BEH), and McBE Pharma, Inc., but sold or dissolved these subsidiaries between December 2023 and April 2024 and now manages operations directly [S1].
• The company currently outsources manufacturing and OEM services following the disposal of BEP in December 2023 [S1, S2].
• Bio Essence Corp is headquartered in Irvine, California, and has 4 full-time employees [S1].
• The company operates in a single reportable segment: manufacture/OEM and sale of health supplement products [S2].
• Revenue recognition follows ASC 606 with sales recognized upon delivery to customers; revenues include sales of goods and manufacture/OEM services [S2].
• The company’s return policy allows returns for damaged or defective products within 30 days, with custom formulas and capsules non-returnable; returns were immaterial in recent periods [S2].
• For the fiscal year ended December 31, 2025, Bio Essence reported revenues of approximately $1.9 million and net income of about $896,000 [S1].
• As of December 31, 2025, the company had cash and equivalents of $28,741, current assets of $422,377, and current liabilities of $2,439,211, resulting in a low current ratio of 0.17 and cash ratio of 0.01, indicating liquidity constraints [S1].
• The company had an accumulated deficit of approximately $10.58 million as of September 30, 2025, and total stockholders’ equity was negative $3.1 million [S2].
• Bio Essence had 38,009,000 shares of common stock issued and outstanding as of the latest filings [S2].
• The company faced a legal complaint filed in February 2026 alleging breach of contract and lease obligations related to a commercial space, with claimed damages of approximately $1.5 million; the company denies the allegations and plans counterclaims [S1].
• In February 2026, Bio Essence announced the commencement of a Regulation A Tier 2 offering to raise up to $5.0 million [N1].